News For LGND From The Last 14 Days Check below for free stories on LGND the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 7, 2012
|
| 16:19 EDT |  | LGND |
| | 16:17 EDT |  | LGND |
| | 16:16 EDT | | LGND |
|
|
February 2, 2012
|
| 06:00 EDT | | LGND |
| theflyonthewall.com: | Ligand Pharmaceuticals' Melphalan shows succesful results in Phase II trial | | Ligand Pharmaceuticals (LGND) provided results from the Phase II study of its Captisol-enabled, propylene glycol-free Melphalan program. The Phase II study was completed in late 2011 and compared the safety, tolerability and pharmacokinetic profiles of the PG-free Melphalan intravenous formulation and the current clinically-used intravenous formulation of melphalan, sold by GlaxoSmithKline (GSK) as Alkeran for Injection, for multiple myeloma patients undergoing autologous transplantation. The Captisol-enabled product is expected to allow for longer administration durations and slower infusion rates, potentially enabling a higher dose intensity of pre-transplant chemotherapy. The new PG-free Melphalan was bioequivalent to Alkeran per guidance requirements, while also demonstrating a marginally higher systemic drug exposure of the multiple myeloma patients. Based on the successful Phase II results, the follow-on Pivotal study will utilize a dosing regimen comparable to Alkeran. :theflyonthewall.com |
|
|
|
Subscribe for More Information